For instance, the risk of developing nivolumab-destructive thyroiditis is known to be significantly higher in patients with pre-treatment anti-thyroid antibodies (namely, anti-peroxidase and anti-thyroglobulin antibodies) (Osorio et al., 2017; Kobayashi et al., 2018; Basak et al., 2020). This evidence concerns the gene TG and thyroid gland disorder.